5 Citations (Scopus)

Abstract

Background: Parkinson's disease (PD) is a progressive disorder of the central nervous system. The prevalence of PD varies considerably by age group; it has a higher prevalence in patients aged 60 years and more. Several studies have shown that statin, a cholesterol-lowering medication, reduces the risk of developing PD, but evidence for this is so far inconclusive. The objective of this study is to evaluate the association between statin use and the risk of developing PD. Methods: PubMed, EMBASE, and the bibliographies of articles were searched for studies published between January 1, 1990, and January 1, 2017, which reported on the association between statin use and PD. Articles were included if they (1) were published in English, (2) reported patients treated with statin, and the outcome of interest was PD, (3) provided OR/HR with 95% CI or sufficient information to calculate the 95% CI. All abstracts, full-text articles, and sources were reviewed, with duplicate data excluded. Summary relative risk (RRs) with 95% CI was pooled using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: We selected 16 out of 529 unique abstracts for full-text review using our selection criteria, and 13 out of these 16 studies, comprising 4,877,059 persons, met all of our inclusion criteria. The overall pooled RR of PD was 0.70 (95% CI 0.58-0.84) with significant heterogeneity between estimates (I2 = 93.41%, p = 0.000) for the random-effects model. In subgroup analysis, the greater decreased risk was found in studies from Asia (RR 0.62 95% CI 0.51-0.76), whereas a moderate reduction was observed in studies from North America (RR 0.69 95% CI 0.47-1.00), but less reduction was observed in studies from Europe (RR 0.86 95% CI 0.80-0.92). Also, long-term statin use, simvastatin, and atorvastatin showed a higher rate of reduction with significance heterogeneity. Conclusion: Our results showed that statin use is significantly associated with a lower risk of developing PD. Physicians should consider statin drug therapy, monitor its outcomes, and empower their patients to improve their knowledge, therapeutic outcomes, and quality of life. However, preventive measures and their associated mechanisms must be further assessed and explored.

Original languageEnglish
Pages (from-to)142-151
Number of pages10
JournalNeuroepidemiology
Volume49
Issue number3-4
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Observational Studies
Parkinson Disease
Meta-Analysis
Simvastatin
Central Nervous System Diseases
Bibliography
North America
PubMed
Patient Selection
Age Groups
Cholesterol
Quality of Life
Physicians
Drug Therapy

Keywords

  • Heterogeneity
  • Hypertension
  • Parkinson's disease
  • Statins
  • Stroke

ASJC Scopus subject areas

  • Epidemiology
  • Clinical Neurology

Cite this

Exploring the Association between Statin Use and the Risk of Parkinson's Disease : A Meta-Analysis of Observational Studies. / Poly, Tahmina Nasrin; Islam, Md Mohaimenul; Walther, Bruno Andreas; Yang, Hsuan Chia; Nguyen, Phung Anh; Huang, Chih Wei; Shabbir, Syed Abdul; Li, Yu Chuan Jack.

In: Neuroepidemiology, Vol. 49, No. 3-4, 01.12.2017, p. 142-151.

Research output: Contribution to journalArticle

@article{66425e689f304f8a81050f880a4f9401,
title = "Exploring the Association between Statin Use and the Risk of Parkinson's Disease: A Meta-Analysis of Observational Studies",
abstract = "Background: Parkinson's disease (PD) is a progressive disorder of the central nervous system. The prevalence of PD varies considerably by age group; it has a higher prevalence in patients aged 60 years and more. Several studies have shown that statin, a cholesterol-lowering medication, reduces the risk of developing PD, but evidence for this is so far inconclusive. The objective of this study is to evaluate the association between statin use and the risk of developing PD. Methods: PubMed, EMBASE, and the bibliographies of articles were searched for studies published between January 1, 1990, and January 1, 2017, which reported on the association between statin use and PD. Articles were included if they (1) were published in English, (2) reported patients treated with statin, and the outcome of interest was PD, (3) provided OR/HR with 95{\%} CI or sufficient information to calculate the 95{\%} CI. All abstracts, full-text articles, and sources were reviewed, with duplicate data excluded. Summary relative risk (RRs) with 95{\%} CI was pooled using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: We selected 16 out of 529 unique abstracts for full-text review using our selection criteria, and 13 out of these 16 studies, comprising 4,877,059 persons, met all of our inclusion criteria. The overall pooled RR of PD was 0.70 (95{\%} CI 0.58-0.84) with significant heterogeneity between estimates (I2 = 93.41{\%}, p = 0.000) for the random-effects model. In subgroup analysis, the greater decreased risk was found in studies from Asia (RR 0.62 95{\%} CI 0.51-0.76), whereas a moderate reduction was observed in studies from North America (RR 0.69 95{\%} CI 0.47-1.00), but less reduction was observed in studies from Europe (RR 0.86 95{\%} CI 0.80-0.92). Also, long-term statin use, simvastatin, and atorvastatin showed a higher rate of reduction with significance heterogeneity. Conclusion: Our results showed that statin use is significantly associated with a lower risk of developing PD. Physicians should consider statin drug therapy, monitor its outcomes, and empower their patients to improve their knowledge, therapeutic outcomes, and quality of life. However, preventive measures and their associated mechanisms must be further assessed and explored.",
keywords = "Heterogeneity, Hypertension, Parkinson's disease, Statins, Stroke",
author = "Poly, {Tahmina Nasrin} and Islam, {Md Mohaimenul} and Walther, {Bruno Andreas} and Yang, {Hsuan Chia} and Nguyen, {Phung Anh} and Huang, {Chih Wei} and Shabbir, {Syed Abdul} and Li, {Yu Chuan Jack}",
year = "2017",
month = "12",
day = "1",
doi = "10.1159/000480401",
language = "English",
volume = "49",
pages = "142--151",
journal = "Neuroepidemiology",
issn = "0251-5350",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - Exploring the Association between Statin Use and the Risk of Parkinson's Disease

T2 - A Meta-Analysis of Observational Studies

AU - Poly, Tahmina Nasrin

AU - Islam, Md Mohaimenul

AU - Walther, Bruno Andreas

AU - Yang, Hsuan Chia

AU - Nguyen, Phung Anh

AU - Huang, Chih Wei

AU - Shabbir, Syed Abdul

AU - Li, Yu Chuan Jack

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: Parkinson's disease (PD) is a progressive disorder of the central nervous system. The prevalence of PD varies considerably by age group; it has a higher prevalence in patients aged 60 years and more. Several studies have shown that statin, a cholesterol-lowering medication, reduces the risk of developing PD, but evidence for this is so far inconclusive. The objective of this study is to evaluate the association between statin use and the risk of developing PD. Methods: PubMed, EMBASE, and the bibliographies of articles were searched for studies published between January 1, 1990, and January 1, 2017, which reported on the association between statin use and PD. Articles were included if they (1) were published in English, (2) reported patients treated with statin, and the outcome of interest was PD, (3) provided OR/HR with 95% CI or sufficient information to calculate the 95% CI. All abstracts, full-text articles, and sources were reviewed, with duplicate data excluded. Summary relative risk (RRs) with 95% CI was pooled using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: We selected 16 out of 529 unique abstracts for full-text review using our selection criteria, and 13 out of these 16 studies, comprising 4,877,059 persons, met all of our inclusion criteria. The overall pooled RR of PD was 0.70 (95% CI 0.58-0.84) with significant heterogeneity between estimates (I2 = 93.41%, p = 0.000) for the random-effects model. In subgroup analysis, the greater decreased risk was found in studies from Asia (RR 0.62 95% CI 0.51-0.76), whereas a moderate reduction was observed in studies from North America (RR 0.69 95% CI 0.47-1.00), but less reduction was observed in studies from Europe (RR 0.86 95% CI 0.80-0.92). Also, long-term statin use, simvastatin, and atorvastatin showed a higher rate of reduction with significance heterogeneity. Conclusion: Our results showed that statin use is significantly associated with a lower risk of developing PD. Physicians should consider statin drug therapy, monitor its outcomes, and empower their patients to improve their knowledge, therapeutic outcomes, and quality of life. However, preventive measures and their associated mechanisms must be further assessed and explored.

AB - Background: Parkinson's disease (PD) is a progressive disorder of the central nervous system. The prevalence of PD varies considerably by age group; it has a higher prevalence in patients aged 60 years and more. Several studies have shown that statin, a cholesterol-lowering medication, reduces the risk of developing PD, but evidence for this is so far inconclusive. The objective of this study is to evaluate the association between statin use and the risk of developing PD. Methods: PubMed, EMBASE, and the bibliographies of articles were searched for studies published between January 1, 1990, and January 1, 2017, which reported on the association between statin use and PD. Articles were included if they (1) were published in English, (2) reported patients treated with statin, and the outcome of interest was PD, (3) provided OR/HR with 95% CI or sufficient information to calculate the 95% CI. All abstracts, full-text articles, and sources were reviewed, with duplicate data excluded. Summary relative risk (RRs) with 95% CI was pooled using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: We selected 16 out of 529 unique abstracts for full-text review using our selection criteria, and 13 out of these 16 studies, comprising 4,877,059 persons, met all of our inclusion criteria. The overall pooled RR of PD was 0.70 (95% CI 0.58-0.84) with significant heterogeneity between estimates (I2 = 93.41%, p = 0.000) for the random-effects model. In subgroup analysis, the greater decreased risk was found in studies from Asia (RR 0.62 95% CI 0.51-0.76), whereas a moderate reduction was observed in studies from North America (RR 0.69 95% CI 0.47-1.00), but less reduction was observed in studies from Europe (RR 0.86 95% CI 0.80-0.92). Also, long-term statin use, simvastatin, and atorvastatin showed a higher rate of reduction with significance heterogeneity. Conclusion: Our results showed that statin use is significantly associated with a lower risk of developing PD. Physicians should consider statin drug therapy, monitor its outcomes, and empower their patients to improve their knowledge, therapeutic outcomes, and quality of life. However, preventive measures and their associated mechanisms must be further assessed and explored.

KW - Heterogeneity

KW - Hypertension

KW - Parkinson's disease

KW - Statins

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85039156497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039156497&partnerID=8YFLogxK

U2 - 10.1159/000480401

DO - 10.1159/000480401

M3 - Article

AN - SCOPUS:85039156497

VL - 49

SP - 142

EP - 151

JO - Neuroepidemiology

JF - Neuroepidemiology

SN - 0251-5350

IS - 3-4

ER -